Anti-TIGIT Shows Promise in Unresectable Liver Cancer

(MedPage Today) -- Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates and improved survival for patients with unresectable hepatocellular carcinoma, a randomized phase Ib...